华邦健康(002004) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for the current period is CNY 2,975,546,798.68, a decrease of 12.46% compared to the same period last year[9]. - Net profit attributable to shareholders of the listed company is CNY 177,137,767.78, an increase of 5.05% year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY 168,985,255.18, reflecting a 4.78% increase compared to the previous year[9]. - The net profit for the first quarter was 294,842,240.23 CNY, a decrease from 319,793,662.55 CNY in the previous year, representing a decline of approximately 7.3%[44]. - The total profit amounted to 366,979,165.37 CNY, down from 478,322,104.63 CNY, indicating a decrease of about 23.2% year-over-year[44]. - The company's operating profit was 373,052,903.14 CNY, compared to 479,840,467.75 CNY in the same period last year, reflecting a decline of approximately 22.2%[44]. - The basic earnings per share increased to 0.0895 CNY from 0.0852 CNY, showing a growth of about 2.7%[44]. Cash Flow - The net cash flow from operating activities shows a significant decline of 108.00%, with a current value of CNY -12,813,669.92[9]. - Net cash flow from operating activities turned negative at -¥12,813,669.92 compared to ¥160,139,339.82, a decline of 108.00% attributed to decreased sales volume[34]. - Cash inflow from investment activities totaled ¥2,619,725,609.42, an increase from ¥2,055,850,849.49 in the previous period[25]. - Cash outflow for investment activities was ¥2,667,219,986.51, significantly higher than ¥2,029,269,337.09 in the previous period[25]. - The company reported a net cash flow from financing activities of ¥271,341,170.39, compared to ¥41,768,134.81 in the previous period[25]. - The net cash outflow from financing activities was -7,096,160.62 CNY, an improvement compared to -143,352,411.67 CNY in the previous year[46]. - The total cash outflow from financing activities was 1,695,183,231.01 CNY, compared to 2,341,225,774.83 CNY in the previous year, reflecting a decrease of approximately 27.6%[46]. - The company reported a foreign exchange impact of -11,413,514.64 CNY on cash and cash equivalents, contrasting with a positive impact of 5,674,000.87 CNY in the previous year[46]. Assets and Liabilities - Total assets at the end of the reporting period amount to CNY 30,225,558,790.97, representing a 0.67% increase from the end of the previous year[9]. - Total liabilities amounted to ¥13,380,018,004.07, slightly down from ¥13,473,613,165.12 in the previous period[22]. - Shareholders' equity attributable to the listed company is CNY 10,368,342,116.43, up by 1.73% compared to the previous year[9]. - Total equity attributable to shareholders reached ¥10,368,342,116.43, up from ¥10,191,961,981.05 in the previous period[22]. - Deferred income increased to ¥305,678,087.18 from ¥278,214,493.71, indicating a growth of about 9.9%[22]. Investments and Subsidiaries - The company established a new subsidiary, Chongqing Songshan Membership Hospital Co., Ltd., with a registered capital of CNY 5 million, aiming to integrate medical resources[18]. - The company reported a decrease in trading financial assets by 32.53%, primarily due to the redemption of financial products during the reporting period[14]. - Investment income decreased significantly to ¥10,000,471.18 from ¥95,932,564.71, a decline of 89.58% due to reduced investment income from associated enterprises[34]. - Accounts receivable financing decreased by 30.14%, mainly due to a reduction in notes receivable[14]. - Contract liabilities decreased by 52.24%, attributed to the delivery of goods during the reporting period[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 89,791, with the largest shareholder, Tibet Huibang Technology Co., Ltd., holding 18.71%[34]. - The top ten shareholders include Tibet Huibang Technology Co., Ltd. (18.71%), Zhang Songshan (5.91%), and Dong Xiaoming (3.58%) among others[34]. Research and Development - Research and development expenses increased to ¥101,564,101.36 from ¥83,364,496.79, marking a growth of approximately 21.8%[22].